Search Results 2461-2470 of 18201 for rheumatoid arthritis

  1. A Study Evaluating The Safety, Efficacy, And Pharmacokinetics Of Mosunetuzumab And A Combined Regimen Of Mosunetuzumab And Venetoclax In Participants With Relapsed Or Refractory Chronic Lymphocytic Leukemia - Mayo Clinic

    ... factor agents) within 2 weeks prior to the first dose of study treatment; any other anti-cancer therapy, whether investigational or approved, including but ...

  2. Publications - Jeremy C. Jones, M.D. - Mayo Clinic

    Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2017 Jun ...

  3. Publications - Katie N. Hunt, M.D. - Mayo Clinic

    ... factor: a case-control study. Breast Cancer Res. 2016 Apr 26; 18 (1):42. View PubMed; Conners AL, Jones KN, Hruska CB, Geske JR, Boughey JC, Rhodes DJ. Direct ...

  4. Publications - Attila Kumanovics, M.D. - Mayo Clinic

    ... factor type A domain protein. Immunogenetics. 2001 Feb; 53 (1):64-8. View PubMed; Jones EP, Kumanovics A, Yoshino M, Fischer Lindahl K. Mhc class I and non ...

  5. Publications - Jennifer L. Herrick, M.D. - Mayo Clinic

    High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and ...

  6. RESET-SLE: A Phase 1/​2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus - Mayo Clinic

    * A clinical diagnosis of SLE, based on the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for ...

  7. Technical Reports - Department of Quantitative Health Sciences - Mayo Clinic Research

    Population attributable risk (PAR) is a function of time because both the prevalence of a risk factor and its effect on exposed individuals may change over ...

  8. A Study to Evaluate Preoperative Oral Microbiota-Based Investigational New Drug to Target Immune Response in Patients with Operable Stage I-III Breast Cancer - Mayo Clinic

    Estrogen receptor (ER) and/or progesterone receptor (PR) positive ≥ 10%, and no human epidermal growth factor receptor 2 (HER2) amplification or overexpression ...

  9. Rotator Cuff Injury Clinical Trials - Mayo Clinic Research

    ... arthritis. . Mayo Clinic Footer. Request Appointment · Give Now · Contact Us · About Mayo Clinic · Employees · Site Map · About This Site. Legal Conditions and ...

  10. Adult health What's New - Mayo Clinic

    Use a lot of sunscreen with a sun protection factor (SPF) of 30 or higher. Follow other basic skin care steps, too, such as not using strong soaps and ...